S1071
Clinical – Upper GI
ESTRO 2026
1 Medical School of Heinrich Heine University of Dusseldorf, Heinrich Heine University, Dusseldorf, Germany. 2 Radiation Oncology, University of Bielefeld, Bielefeld, Germany. 3 Radiation Oncology, Heinrich Heine University, Dusseldorf, Germany. 4 Institute for Transplantation Diagnostics and Cellular Therapeutics, Heinrich Heine University, Dusseldorf, Germany. 5 Gastroenterology, Heinrich Heine University, Dusseldorf, Germany. 6 Surgery, Heinrich Heine University, Dusseldorf, Germany Purpose/Objective: Hepatocellular carcinoma (HCC) remains a major global health burden. While radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) are established loco-regional therapies, stereotactic body radiotherapy (SBRT) has emerged as a non-invasive alternative. This umbrella meta-analysis aimed to compare the efficacy of SBRT with RFA and TACE in terms of overall survival (OS) and local control (LC). Material/Methods: A systematic literature search (PubMed, Web of Science) was conducted according to PRISMA guidelines. Studies reporting hazard ratios (HR) or odds ratios (OR) for OS and/or LC were included. Seven eligible studies (n=7) were analyzed. Pooled HRs were calculated for SBRT versus RFA and SBRT versus TACE. Results: SBRT demonstrated significantly improved LC compared to both RFA (HR = 0.53; 95% CI: 0.40–0.69) and TACE (HR = 0.48; 95% CI: 0.30–0.78). However, no significant differences in OS were observed when comparing SBRT with RFA (HR = 0.98; 95% CI: 0.81– 1.19) or TACE (HR = 0.76; 95% CI: 0.55–1.04). Conclusion: SBRT provides superior local tumor control compared to RFA and TACE, but without a demonstrated survival advantage. Prospective trials with standardized reporting of liver function, disease etiology, and treatment-related toxicity are warranted to better define the role of SBRT in individualized HCC management. Keywords: hepatocellular carcinoma, SBRT, RFA, TACE
Conclusion: Adaptive MR-guided SABR was well-tolerated and effective for primary and metastatic liver tumours. This novel organ-wise DIR can aid evaluation of accumulated dose for MR-guided adaptive liver SABR patients and allow for establishment of dose-side effect relationships. References: 1. Boldrini L, Corradini S, Gani C, Henke L, Hosni A, Romano A, et al. MR-Guided Radiotherapy for Liver Malignancies. Front Oncol [Internet]. 2021;11. Available from: www.frontiersin.org2. de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, Brown K, Choudhury A, et al. The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. Front Oncol. 2020;10. 3. Daly M, Osorio EV, Choudhury A, McWilliam A, Radhakrishna G, Eccles CL. Evaluation of DIR strategies for OAR dose accumulation in MR- guided pancreas SABR. Radiotherapy and Oncology. 2024;(197):S336-337. Keywords: liver SABR, deformable registration, outcomes
Digital Poster Highlight 1212
Phase II study of envafolimab combined with endostar and concurrent chemoradiotherapy in treatment of unresectable locally advanced ESCC baosheng Li, Zhao Qian Department of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
Digital Poster 969
Comparative Effectiveness of SBRT versus RFA and TACE in Hepatocellular Carcinoma: An Umbrella- Metaanalysis Ilyas Gencer 1 , Muentaz Koeksal 2 , Vincent Rothweiler 3 , Wilfried Budach 2 , Johannes Fischer 4 , Torsten Feldt 5 , Björn Eric Ole Jensen 5 , Wolfram Trudo Knoefel 6 , Christoph Roderburg 5 , Edwin Bölke 2
Purpose/Objective:
Made with FlippingBook - Share PDF online